News
Tarsus Pharmaceuticals Welcomes Aziz Mottiwala as Chief Commercial Officer and Relocates to Larger Irvine Headquarters
Mr. Mottiwala Brings over 20 Years of Biopharmaceutical Experience to Growing Tarsus Leadership Team
Tarsus Pharmaceuticals Announces Appointment of New COO and CFO
Sesha Neervannan, PhD, to assume position of Chief Operating Officer; Leo Greenstein to assume position of Chief Financial Officer
Tarsus Presents Positive Results of the Jupiter Study, a Phase 2b Randomized Controlled Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Blepharitis Due to Demodex Infestation, at AOA 2020 Virtual Meeting
The first randomized controlled study of TP-03 for the treatment of Demodex Blepharitis continues to show rapid, complete and durable efficacy with no treatment-related adverse events.
Tarsus Pharmaceuticals Announces Positive Results of the Mars study, a Phase 2a Study of the Efficacy and Safety of TP-03 to Treat Demodex Blepharitis, at ARVO 2020 Virtual Meeting
This first clinical trial of TP-03 for Demodex Blepharitis showed rapid, complete, and durable efficacy with no serious adverse effects.
Tarsus CEO Bobak Azamian, MD, PHD Addresses Unmet Needs In Blepharitis
In January of 2020, Tarsus raised $60 million Series B financing round to initiate Phase 2b/3 trial in the U.S. of their lead product TP-03 for Demodex blepharitis. In this episode, Bobby Azamian shares his background and path to ophthalmology, details on their clinical trials and practical advice for entrepreneurs.
Tarsus Pharmaceuticals Raises $60 Million in Series B Financing
Capital to enable Phase 2b/3 trial for lead product TP-03 in Demodex blepharitis and additional clinical pipeline development